Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Tokyo - Delayed Quote JPY

Taiko Pharmaceutical Co.,Ltd. (4574.T)

Compare
256.00
-11.00
(-4.12%)
At close: April 4 at 3:30:00 PM GMT+9
Loading Chart for 4574.T
  • Previous Close 267.00
  • Open 262.00
  • Bid 256.00 x --
  • Ask 257.00 x --
  • Day's Range 252.00 - 262.00
  • 52 Week Range 252.00 - 495.00
  • Volume 328,400
  • Avg. Volume 146,313
  • Market Cap (intraday) 12.85B
  • Beta (5Y Monthly) 0.33
  • PE Ratio (TTM) --
  • EPS (TTM) -47.62
  • Earnings Date May 8, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 29, 2021
  • 1y Target Est --

Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines in Japan and internationally. The company provides OTC medicines for the treatment of loose stools, diarrhea, vomiting, food and water poisoning symptoms, and toothache; and quasi-drugs for regulation of intestinal movements, relieves stomach distention, loose stools, and constipation. It manufactures and sells infection control products. Taiko Pharmaceutical Co.,Ltd. exports its products. The company was incorporated in 1946 and is headquartered in Osaka, Japan.

www.seirogan.co.jp

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4574.T

View More

Performance Overview: 4574.T

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

4574.T
22.66%
Nikkei 225 (^N225)
15.33%

1-Year Return

4574.T
29.48%
Nikkei 225 (^N225)
15.07%

3-Year Return

4574.T
57.76%
Nikkei 225 (^N225)
21.79%

5-Year Return

4574.T
84.04%
Nikkei 225 (^N225)
89.56%

Compare To: 4574.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4574.T

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    12.85B

  • Enterprise Value

    10.30B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.06

  • Price/Book (mrq)

    1.66

  • Enterprise Value/Revenue

    1.67

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.27%

  • Return on Assets (ttm)

    2.99%

  • Return on Equity (ttm)

    12.22%

  • Revenue (ttm)

    6.29B

  • Net Income Avi to Common (ttm)

    898M

  • Diluted EPS (ttm)

    -47.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.53B

  • Total Debt/Equity (mrq)

    25.46%

  • Levered Free Cash Flow (ttm)

    -330.75M

Research Analysis: 4574.T

View More

Company Insights: 4574.T

Research Reports: 4574.T

View More

People Also Watch